To develop a therapy that reduces inflammation, we will have to also understand the biological rationale of the observed increase of RvD1, RvE3 and RvT4 concentrations in slow progressing ALS, and the relatively low RvD1-sensitive GPR32-expressing B and T cell frequencies in pwALS in our ALS cohorts. Here, GPR32 is linked to amyotrophic lateral sclerosis.